FDA's evaluation of the abuse-deterrence properties of Egalet Corp.'s Arymo ER (morphine sulfate extended-release) suggests an oral deterrence claim may be the hardest to come by for the long-acting opioid.
Arymo has been formulated with physicochemical properties intended to deter abuse by the oral (chewing and crushing), intranasal and intravenous...




